Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

AbbVie is presented as the superior dividend investment despite Pfizer's higher 6.1% yield, supported by a 53-year dividend-growth record, a 5.5% quarterly dividend increase to $1.73, and a lower FCF payout ratio of 65% versus Pfizer's 89%. AbbVie reported Q2 sales of $16.9 billion, up 10.2% year over year, and EPS of $2.03, up 290%, as Skyrizi and Rinvoq generated $5.5 billion and $2.52 billion in revenue, respectively. The article contrasts AbbVie's post-Humira recovery with Pfizer's estimated $17 billion-$18 billion annual revenue exposure to patent expirations from 2026-2028, although AbbVie carries $62 billion of long-term debt and is pursuing a $10.9 billion acquisition of Apogee Therapeutics.

Analysis

The relevant valuation debate is not dividend yield but durability of post-LOE free cash flow. ABBV has shifted from a single-product cliff to a concentrated two-asset immunology franchise; that supports dividend coverage today but creates a new concentration risk if payer restrictions, safety signals, or competition from J&J’s Tremfya/other IL-23 therapies slow prescription share. The market is likely to reward ABBV with a premium multiple only while Skyrizi/Rinvoq growth remains sufficient to fund both business-development spending and capital returns without leverage drifting higher.

PFE’s yield is better viewed as a credit-and-earnings-duration signal than an income opportunity. The combination of portfolio erosion, integration requirements from Seagen, and incremental pipeline spending means each dollar of lost legacy revenue has disproportionate consequences for FCF conversion, debt reduction, and the credibility of future dividend growth. Conversely, PFE has a meaningful re-rating setup over 6-18 months if ADC launches and oncology execution demonstrate that the acquired portfolio can replace declining cash flows; current pessimism leaves more upside to a clean execution surprise than ABBV, but the proof burden is high.

Near-term, this article is unlikely to move either large-cap stock materially. The actionable catalyst calendar is quarterly: ABBV immunology net-sales growth, gross-to-net/payer commentary, and leverage after acquisitions; PFE oncology growth, LOE erosion rates, net debt reduction, and any revision to dividend or FCF guidance. A key contrarian point is that ABBV's apparent cash-flow superiority can narrow quickly if its next-generation franchise matures earlier than expected, whereas PFE’s patent-cliff risk is widely recognized and partly reflected in its valuation.

Key Decisions for Investors

• Maintain a 6-12 month quality pair: long ABBV / short PFE in equal dollar exposure. Target relative outperformance of 10-15%; reassess if PFE raises medium-term FCF guidance or ABBV reports two consecutive quarters of material Skyrizi/Rinvoq deceleration versus consensus.
• Do not add to ABBV solely on dividend optics. Add only after earnings confirm immunology growth and stable gross margin; use a 8-10% downside stop from entry because the principal risk is franchise concentration rather than near-term dividend coverage.
• For event-driven investors, buy limited-risk PFE call spreads 9-15 months out only if oncology revenue and net-debt reduction trend above guidance at the next report. The asymmetric upside is a multiple re-rating on Seagen validation; maximum loss should be confined to premium because LOE-related estimate cuts can persist for several quarters.
• Monitor APGE transaction terms and regulatory/closing status before assigning any strategic value to ABBV. If the deal requires unexpectedly large upfront cash, materially worsens leverage, or faces efficacy differentiation concerns, reduce ABBV exposure rather than assuming pipeline optionality is accretive.